02198nas a2200337   4500000000100000008004100001260001300042653001500055653001000070653001200080653001400092100001100106700001200117700001200129700001200141700001200153700001300165700001500178700001000193700001200203700001200215700001300227700006600240700003400306245008000340856006500420300001100485490000700496520134300503022001401846       2013                            d  c2013 Dec10aGuidelines10aJapan10aleprosy10aTreatment1 aGoto M1 aNogam R1 aOkano Y1 aGidoh M1 aYotsu R1 aIshida Y1 aKitajima S1 aKai M1 aIshii N1 aOzaki M1 aHatano K1 aAd Hoc Committee on Treatment Guideline and Judgment of Cure 1 aJapanese Leprosy Association 00a[Guideline for the treatment of Hansen's disease in Japan (third edition)].  uhttps://www.jstage.jst.go.jp/article/hansen/82/3/82_143/_pdf  a143-840 v823 a<p>ad hoc committee of Japanese Leprosy Association recommends revised standard treatment protocol of leprosy in Japan, which is a modification of World Health Organization's multidrug therapy (WHO/MDT, 2010). For paucibacillary (PB) leprosy, 6 months treatment by rifampicin and dapsone (MDT/PB) is enough. However, for high bacterial load multibacillary (MB) leprosy, 12 months treatment seems insufficient. Thus, (A) For MB with bacterial index (BI) &gt; 3 before treatment, 2 years treatment by rifampicin, dapsone and clofazimine (MDT/MB) is necessary. When BI becomes negative and active lesion is lost within 2 years, no maintenance therapy is necessary. When BI is still positive, one year of MDT/MB is added (3 years in total), followed by maintenance therapy by dapsone and clofazimine until BI negativity and loss of active lesions. (B) For MB with BI &lt; 3 or fresh MB (less than 6 months after the onset of the disease) with BI &gt; 3, 1 year treatment by MDT/MB is necessary. When BI becomes negative and active lesion is lost within one year, no maintenance therapy is necessary. When BI is still positive or active lesion is remaining, additional therapy with MDT/MB for one more year is recommended. Brief summary of diagnosis, purpose of therapy, character of drugs, and prevention of deformity is also described.</p>
  a1342-3681